Great Novel Therapeutics Biotech & Medicals (7427.TWO)
TWD 36.15
(0.14%)
TWD 36.15
(0.14%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | -53.34 Million | -65.81 Million | -33.91 Million | -41.88 Million | -18.5 Million |
| Net Income | -61.54 Million | -55.77 Million | -35.85 Million | -31.26 Million | -29.87 Million |
| Depreciation & Amortization | 6.53 Million | 1.82 Million | 1.49 Million | 1.03 Million | 1.02 Million |
| Deferred income taxes | - | - | - | - | - |
| Stock-based compensation | 11.28 Million | 4.91 Million | 3.66 Million | 1.21 Million | 647 Thousand |
| Change in working capital | -9.59 Million | -16.75 Million | -3.19 Million | -15.43 Million | 9.63 Million |
| Other non-cash items | -5.24 Million | -936 Thousand | -515 Thousand | 21 Thousand | 57 Thousand |
| Investing Cash Flow | -184.42 Million | -89.2 Million | -90.31 Million | 430 Thousand | -30.9 Million |
| Investments in PPE | -20.86 Million | -12.57 Million | -28 Million | -13.07 Million | - |
| Acquisitions | 120 Thousand | - | - | - | - |
| Investment purchases | -273.8 Million | -136.5 Million | -62.31 Million | - | - |
| Sales/Maturities of investments | 113.3 Million | 62.31 Million | - | 13.5 Million | - |
| Other Investing Activities | -3.18 Million | -2.44 Million | -90.28 Million | 447 Thousand | -30.9 Million |
| Financing Cash Flow | 306.24 Million | 203.31 Million | 120 Million | 83.59 Million | 27.68 Million |
| Debt repayment | -1.24 Million | - | - | - | - |
| Dividends payments | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - |
| Common Stock Issuance | 307.48 Million | 203.31 Million | 120 Million | 83.59 Million | - |
| Other Financing Activities | 307.48 Million | 203.31 Million | 120 Million | 83.59 Million | 27.68 Million |
| Accounts receivables | -92 Thousand | - | -38 Thousand | 90 Thousand | -90 Thousand |
| Accounts payables | - | - | - | - | - |
| Inventory | -6.16 Million | - | - | 17 Thousand | 2000.00 |
| Other working capital | -4.39 Million | -16.75 Million | -3.15 Million | -15.53 Million | 9.72 Million |
| Cash at beginning of period | 111.07 Million | 62.78 Million | 67.02 Million | 24.87 Million | 46.6 Million |
| Cash at end of period | 179.55 Million | 111.07 Million | 62.78 Million | 67.02 Million | 24.87 Million |
| Capital Expenditure | -20.86 Million | -12.57 Million | -28 Million | -13.07 Million | - |
| Effect of forex changes on cash | - | - | - | - | - |
| Net cash flow / Change in cash | 68.47 Million | 48.29 Million | -4.23 Million | 42.14 Million | -21.73 Million |
| Free Cash Flow | -74.2 Million | -78.38 Million | -61.92 Million | -54.95 Million | -18.5 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -30.97 Million | -30.97 Million | -61.54 Million | -13.47 Million | -13.47 Million | -17.02 Million |
| Depreciation & Amortization | 1.73 Million | 1.73 Million | 6.53 Million | 1.57 Million | 1.57 Million | 561.5 Thousand |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 5.89 Million | - | 11.28 Million | 728.5 Thousand | 728.5 Thousand | 4.91 Million |
| Change in working capital | -1.23 Million | -1.23 Million | -9.59 Million | 1.19 Million | 1.19 Million | -6.52 Million |
| Other non-cash items | 1.06 Million | 6.96 Million | -5.24 Million | -8.86 Million | -8.86 Million | 9.4 Million |
| Investing Cash Flow | 13.26 Million | 13.26 Million | -184.42 Million | -975.5 Thousand | -975.5 Thousand | -90.41 Million |
| Investments in PPE | -1 Million | -1 Million | -20.86 Million | -1.43 Million | -1.43 Million | -28 Thousand |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | -129 Million | - | -273.8 Million | - | - | - |
| Sales/Maturities of investments | 158 Million | - | 113.3 Million | - | - | - |
| Other Investing Activities | 14.27 Million | 14.27 Million | -3.18 Million | 459 Thousand | 459 Thousand | -90.38 Million |
| Financing Cash Flow | 92.56 Million | 92.56 Million | 306.24 Million | 903 Thousand | 903 Thousand | 152.21 Million |
| Debt repayment | -2.88 Million | - | -1.24 Million | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 186.61 Million | - | 307.48 Million | - | - | - |
| Other Financing Activities | 92.56 Million | 92.56 Million | 307.48 Million | 903 Thousand | 903 Thousand | 152.21 Million |
| Accounts receivables | -134.5 Thousand | -134.5 Thousand | -92 Thousand | 2.45 Million | 2.45 Million | -2.5 Million |
| Accounts payables | - | - | - | - | - | - |
| Inventory | 1.5 Million | 1.5 Million | -6.16 Million | -3.08 Million | -3.08 Million | - |
| Other working capital | -2.6 Million | -2.6 Million | -4.39 Million | 1.82 Million | 1.82 Million | -4.02 Million |
| Cash at beginning of period | 179.55 Million | - | 111.07 Million | - | - | - |
| Cash at end of period | 82.31 Million | 82.31 Million | 179.55 Million | -18.91 Million | -18.91 Million | 53.14 Million |
| Capital Expenditure | -1 Million | -1 Million | -20.86 Million | -1.43 Million | -1.43 Million | -28 Thousand |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -97.23 Million | 82.31 Million | 68.47 Million | -18.91 Million | -18.91 Million | 53.14 Million |
| Free Cash Flow | -24.51 Million | -24.51 Million | -74.2 Million | -20.27 Million | -20.27 Million | -8.68 Million |
SOL
TIRUPATIFL
0896
BAESF
NSARO
APTL